Antibody molecules having specificity for human IL-6
The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
1. A neutralising antibody having specificity for human IL-6 comprising a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO: 5 for CDR-H1, the sequence given in SEQ ID NO: 6 for CDR-H2 and the sequence given in SEQ ID NO: 7 for CDR-H3, and further comprising a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO: 8 for CDR-L1, the sequence given in SEQ ID NO: 9 for CDR-L2 and the sequence given in SEQ ID NO: 10 for CDR-L3.
2. The antibody according to claim 1 wherein the heavy chain comprises the sequence gH13 (SEQ ID NO: 11).
3. The antibody according to claim 1 wherein the light chain comprises the sequence gL10 (SEQ ID NO: 13).
4. A neutralising antibody having specificity for human IL-6, comprising a heavy chain comprising the sequence gH13 (SEQ ID NO: 11) and a light chain comprising the sequence gL10 (SEQ ID NO: 13).
5. A neutralising antibody having specificity for human IL-6, comprising a heavy chain comprising the sequence given in SEQ ID NO: 16 and a light chain comprising the sequence given in SEQ ID NO: 18.
6. A pharmaceutical composition comprising an antibody according to claim 1 , 2 , 3 , 4 or 5 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
7. The pharmaceutical composition according to claim 6 , additionally comprising other active ingredients.